Herceptin® (Trastuzumab) Response

This version of the course is no longer available.
Need multiple seats for your university or lab? Get a quote
The page below is a sample from the LabCE course . Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about (online CE course)
Herceptin® (Trastuzumab) Response

Her2-positive breast cancer patients may not respond to Herceptin® (trastuzumab) for the following reasons:

  • Inaccurate testing, especially by immunohistochemistry (IHC)
  • Inaccurate scoring, especially by IHC
  • Other molecular markers expressed simultaneously, such as Topo IIa and p53
  • Phosphorylation of HER2 itself
  • Other inhibitors in the PI3K pathway, such as PTEN